{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:52:43Z","timestamp":1768341163619,"version":"3.49.0"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.2967\/jnumed.120.261854","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T15:59:04Z","timestamp":1622217544000},"page":"205-211","source":"Crossref","is-referenced-by-count":12,"title":["<sup>131<\/sup>I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors"],"prefix":"10.2967","volume":"63","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Kupferschlaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Reischl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert J.","family":"Handgretinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian la","family":"Foug\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Dittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"2022032309402886000_63.2.205.1","first-page":"1098","article-title":"Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth","volume":"47","author":"Mujoo","year":"1987","journal-title":"Cancer Res."},{"key":"2022032309402886000_63.2.205.2","first-page":"5914","article-title":"Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients","volume":"44","author":"Schulz","year":"1984","journal-title":"Cancer Res."},{"key":"2022032309402886000_63.2.205.3","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(94)90034-5"},{"key":"2022032309402886000_63.2.205.4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920801)70:3<633::AID-CNCR2820700315>3.0.CO;2-F"},{"key":"2022032309402886000_63.2.205.5","doi-asserted-by":"publisher","DOI":"10.2174\/156800910791054167"},{"key":"2022032309402886000_63.2.205.6","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016632013"},{"key":"2022032309402886000_63.2.205.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30578-3"},{"key":"2022032309402886000_63.2.205.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123"},{"key":"2022032309402886000_63.2.205.9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2014-172"},{"key":"2022032309402886000_63.2.205.10","doi-asserted-by":"crossref","first-page":"e00540","DOI":"10.1136\/jitc-2020-000540","article-title":"Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma","volume":"8","author":"Ehlert","year":"2020","journal-title":"J Immunother Cancer."},{"key":"2022032309402886000_63.2.205.11","first-page":"327","article-title":"Pharmaceutical approval update","volume":"40","author":"Gohil","year":"2015","journal-title":"P&T."},{"key":"2022032309402886000_63.2.205.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3925"},{"key":"2022032309402886000_63.2.205.13","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol."},{"key":"2022032309402886000_63.2.205.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"2022032309402886000_63.2.205.15","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(20010101)36:1<227::AID-MPO1055>3.0.CO;2-U"},{"key":"2022032309402886000_63.2.205.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.3807"},{"key":"2022032309402886000_63.2.205.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198310203091601"},{"key":"2022032309402886000_63.2.205.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310213291702"},{"key":"2022032309402886000_63.2.205.19","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3389\/fimmu.2018.01355","article-title":"A comprehensive safety trial of chimeric antibody 14.18 with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children\u2019s Oncology Group study ANBL0931","volume":"9","author":"Ozkaynak","year":"2018","journal-title":"Front Immunol."},{"key":"2022032309402886000_63.2.205.20","doi-asserted-by":"publisher","DOI":"10.1089\/108497802760804763"},{"key":"2022032309402886000_63.2.205.21","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-57-682-903"},{"key":"2022032309402886000_63.2.205.22","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200110000-00009"},{"key":"2022032309402886000_63.2.205.23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26097"},{"key":"2022032309402886000_63.2.205.24","first-page":"1284","article-title":"In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy","volume":"44","author":"Lewis","year":"2003","journal-title":"J Nucl Med."},{"key":"2022032309402886000_63.2.205.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2010.07.003"},{"key":"2022032309402886000_63.2.205.26","doi-asserted-by":"crossref","first-page":"67403","DOI":"10.18632\/oncotarget.11795","article-title":"Correlation between positron emission tomography and Cerenkov luminescence imaging in\u00a0vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model","volume":"7","author":"Maier","year":"2016","journal-title":"Oncotarget."},{"key":"2022032309402886000_63.2.205.27","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2014.07.003"},{"key":"2022032309402886000_63.2.205.28","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1200\/JCO.1998.16.9.3053","article-title":"Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age","volume":"16","author":"Cheung","year":"1998","journal-title":"J Clin Oncol."},{"key":"2022032309402886000_63.2.205.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.048132"},{"key":"2022032309402886000_63.2.205.30","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.7150\/thno.26585","article-title":"Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: curative treatment of HER2-positive breast carcinoma","volume":"8","author":"Cheal","year":"2018","journal-title":"Theranostics."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.120.261854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T16:42:43Z","timestamp":1648053763000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.120.261854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1,31]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.2967\/jnumed.120.261854"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.120.261854","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]}}}